Company / Working Capital
Kiniksa Pharmaceuticals International, plc Working Capital History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$388.0M
FY2025
5-year range
$151.6M / $388.0M
FY2021-FY2025
Trend
+67.8%
vs FY2024
Sector context
#111 of 213
Health Care
What the data says
At $388M, Kiniksa Pharmaceuticals International, plc's working capital ranks #111 of 213 in the Health Care sector. Working Capital has increased for 4 consecutive years, from $152M in FY2021 to $388M in FY2025.
Based on SEC 10-K filings.
$388M in FY2025 with a 5-year CAGR of +5.2%.
Improved from $213M to $388M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +25.6%
- 5-Year CAGR
- +5.2%
- 10-Year CAGR
- -
Sector benchmark
#111 of 213 in Health CareTop 52% of 213This company $388.0M Sector average $934.6M
▼
-58.5% below sector average
Key checks
Key Insights
- Kiniksa Pharmaceuticals International, plc's working capital has grown for 4 consecutive years.
- 5-year CAGR of +5.2%, indicating consistent growth.
- In FY2025, working capital increased 67.8% year-over-year.
- Ranks #111 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $388.0M | +67.8% |
| FY2024 | $231.2M | +8.7% |
| FY2023 | $212.6M | +8.5% |
| FY2022 | $196.0M | +29.3% |
| FY2021 | $151.6M | -49.7% |
| FY2020 | $301.4M | +41.0% |
| FY2019 | $213.8M | -21.2% |
| FY2018 | $271.2M | +813.9% |
| FY2017 | $29.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026